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Socio-demographic, Clinical, and 
Genetic Determinants of Quality of 
Life in Lung Cancer Patients
Jeanne A. Pierzynski1, Yuanqing Ye1, Scott M. Lippman2, Maria A. Rodriguez3, Xifeng Wu  1 & 
Michelle A. T. Hildebrandt1
Patient reported health-related quality of life (QOL) is a major component of the overall well-being 
of cancer patients, with links to prognosis. In 6,420 lung cancer patients, we identified patient 
characteristics and genetic determinants of QOL. Patient responses from the SF-12 questionnaire 
was used to calculate normalized Physical Component Summary (PCS) and Mental Component 
Summary (MCS) scores. Further, we analyzed 218 single nucleotide polymorphisms (SNPs) in the p38 
MAPK signaling pathway, a key mediator of response to cellular and environmental stress, as genetic 
determinants of QOL in a subset of the study population (N = 641). Trends among demographic factors 
for mean PCS and MCS included smoking status (PCS Ptrend < 0.001, MCS Ptrend < 0.001) and education 
(PCS Ptrend < 0.001, MCS Ptrend < 0.001). Similar relationships were seen for MCS. The homozygous rare 
genotype of MEF2B: rs2040562 showed an increased risk of a poor MCS (OR: 3.06, 95% CI: 1.05–8.92, 
P = 0.041). Finally, survival analysis showed that a low PCS or a MCS was associated with increased risks 
of five-year mortality (HR = 1.63, 95% CI: 1.51–1.77, HR = 1.23, 95% CI: 1.16–1.32, respectively) and 
there was a significant reduction in median survival time (Plog-rank < 0.001). These findings suggest that 
multiple factors contribute to QOL in lung cancer patients, and baseline QOL can impact survival.
Newly diagnosed lung cancer patients experience one of the worst symptom burdens1. In recent years, 
health-related quality of life (QOL) has become an important aspect of cancer treatment and research has linked 
improved patient-reported QOL to improved lung cancer survival2,3.
To date, several studies have investigated the role of demographic factors on QOL in cancer patients. African 
American men recently diagnosed with prostate cancer and African American women breast cancer survivors 
reported better emotional well-being compared to Caucasians4,5. Older age has been shown to be a predictor of 
emotional and physical well-being for multiple cancer sites6. Previous studies suggested that women with lung 
cancer report higher rates of depression prior to treatment (49%) than men (29%), and depression is a strong 
indicator of QOL7,8. In small cell lung cancer (SCLC) patients, one study showed that those smoking one year 
post diagnosis exhibited the worst QOL compared to all other smoking categories9, while another study reported 
inconsistent findings with those who continue to smoke following diagnosis reporting worse QOL10. Clinical fac-
tors may also play a role in QOL. SCLC patients reported worse depression and anxiety than non-small cell lung 
cancer (NSCLC) patients7. While evidence suggests that demographic and clinical characteristics are predictors 
of cancer patient QOL, inter-individual variability still remains.
Genetic components may also affect QOL. For example, one study reported an association between three SNPs 
in two genes related to inflammation (LTA and PTGS2) and pain severity, social functioning, and mental health 
in lung cancer survivors11. The p38 MAPK pathway is activated through extracellular stimuli such as proinflam-
matory cytokines including interleukin (IL)-1) and tumor necrosis factor (TNF) alpha12. Once the p38 MAPK 
pathway is activated, the downstream effects ultimately result in changes in cell survival through programmed cell 
death13 and pathway activation can lead to the increased production of more pro-inflammatory cytokines14. This 
pathway is of interest in regards to QOL because it is a key mediator of response to cellular and environmental 
stress. Examples of stress that activate this pathway are pro-inflammatory cytokines (as stated above, such as IL-1 
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and TNF-alpha). Further, because this can result in the production of more pro-inflammatory cytokines, this is 
of interest because elevated levels of pro-inflammatory cytokines have been associated with negative symptoms 
in cancer patients (such as fatigue and depression) of which can negatively impact QOL15. To date, no study has 
examined genetic variation in this pathway in relation to QOL in lung cancer patients. In this study, we assessed 
the relationship between QOL and lung cancer survival and identified determinants of QOL by investigating the 
relationship between patient characteristics and genetic factors.
Results
Host Characteristics. The patient characteristics are shown in Table 1. The mean age was 60.9 years. Most 
patients were whites (83%), married (72.9%), and had completed at least a high school education (57.7%), 17.4% 
were never smokers, 41.2% were never alcohol consumers, and 27.5% of the patients were diagnosed with stage 
IV disease. The distribution of PCS and MCS scores in the study population show that neither score was normally 
distributed, Supplemental Fig. 1.
Relationship between Demographic and Clinical Characteristics and PCS/MCS Scores. 
Comparison of Mean PCS Scores. Table 1 shows patients who had a college degree (41.8, P < 0.001) reported a 
higher mean PCS score when compared to individuals with less than a high school education (35.2). Interestingly, 
current drinkers had a higher mean PCS (41.9, P < 0.001) score compared to never drinkers (37.2). The opposite 
effect was seen for current smokers (36.5, P < 0.001) when compared to never smokers (40.8). When examining 
racial differences, blacks were more likely to have a low mean PCS (35.7, P < 0.001) score compared to whites 
(38.9). The mean PCS score for widowed patients (37.0, P < 0.001) was lower compared to those married (39.2). 
The PCS scores for patients with squamous cell (38.0, P = 0.003) and small cell (36.8, P < 0.001) lung cancer were 
lower than those with adenocarcinoma (39.7). Finally, stage III (41.2, P < 0.001) and stage IV (37.7, P < 0.001) 
lung cancer patients reported worse PCS scores compared to those with stage I (43.9).
Poor PCS Risk. We examined the factors contributing to poor PCS risk as shown in Fig. 1A (Supplemental 
Table 1). When compared to less than a high school education, patients with a college degree had a lower risk 
of reporting a low PCS (OR = 0.50, 95% CI: 0.39–0.64, P < 0.001). When compared to never smokers, former 
smokers had a higher risk of reporting a poor PCS (OR = 1.34, 95% CI: 1.11–1.61, P = 0.002). Current smokers 
(compared to never smokers) had an even larger increased risk of reporting a poor PCS (OR = 1.81, 95% CI: 
1.43–2.31, P < 0.001). Squamous cell lung cancer patients were at a 41% increased risk of a poor PCS (OR = 1.41, 
95% CI: 1.16–1.72, P = 0.001). Individuals diagnosed with stage III (OR = 1.45, 95% CI: 1.15–1.84, P = 0.002) and 
IV (OR = 2.79, 95% CI: 2.23–3.50, P < 0.001) lung cancer were at an increased risk of an unfavorable PCS score.
Comparison of Mean MCS Score. Table 1 showed as participant’s age increased, their MCS score increased 
and the oldest age group reported a higher mean MCS score (70+: 47.5, P < 0.001) compared to the youngest 
age group (<50: 45.4), indicating their perception of their QOL was better than the youngest age group. MCS 
scores for patients who had a high school, vocational, or associates degrees (45.9, P < 0.001) or a college degree 
(47.6, P < 0.001) were higher compared to those who did not finish high school (42.6, Ptrend < 0.001). Asian/
Pacific Islanders (48.3, P = 0.034) reported higher mean MCS scores compared to whites (46.0). The lowest MCS 
score for alcohol usage was seen with former alcohol drinkers (44.5, P = 0.033) and was worse compared to 
never drinkers (45.5). Interestingly, current drinkers (47.1, P < 0.001) reported a higher MCS score compared to 
never drinkers. A downward trend of mean MCS scores was see for former (46.1, P < 0.001) and current (43.6, 
P < 0.001) smokers compared to never smokers (48.0, Ptrend < 0.001). Divorced patients were more likely to have 
a worse mean MCS score (44.1, P < 0.001) compared to married patients (46.3). By histology type, patients with 
small cell lung cancer had the lowest MCS score (43.8, P < 0.001) compared to those with adenocarcinoma (46.6). 
When stratifying by smoking, this relationship was only seen in ever smokers (data not shown). Finally, stage III 
(46.3, P < 0.001) or IV (45.2, P < 0.001) patients reported worse MCS scores compared to those with stage I (49.3) 
lung cancer.
Poor MCS Risk. We examined the factors contributing to poor MCS shown in Fig. 1B (Supplemental Table 2). 
Females were 41% (OR = 1.41, 95% CI: 1.26–1.59, P < 0.001) more likely to report a worse MCS when compared 
to males. Participants with a college degree had a lower risk of reporting a low MCS compared to patients with 
less than a high school education (OR = 0.50, 95% CI: 0.41–0.61, P < 0.001). Asian/Pacific Islanders were more 
likely to report a better MCS (OR = 0.72, 95% CI: 0.54–0.98, P = 0.035) compared to whites. When compared 
to never smokers, former smokers had a higher risk of reporting a poor MCS (OR = 1.40, 95% CI: 1.19–1.65, 
P < 0.001). Current smokers (compared to never smokers) had an even bigger increased risk of reporting a poor 
MCS (OR = 1.69, 95% CI: 1.38–2.06, P < 0.001). Finally, patients diagnosed with stage IV lung cancer have a 
76% (OR = 1.76, 95% CI: 1.43–2.16, P < 0.001) greater risk of reporting a worse MCS score compared to those 
diagnosed with stage I.
The Relationship between Genetic Variants in the p38 MAPK Pathway and PCS/MCS Scores. 
Discovery Phase for PCS and MCS Scores. In the discovery phase, 29 SNPs were associated with PCS score 
(Supplemental Table 3) and 20 SNPS were associated with MCS score (Supplemental Table 4). The most signifi-
cant genetic variant associated with PCS score was TNFRSF1B: rs496888, which was associated with a higher PCS 
score (OR = 0.40, 95% CI: 0.21–0.75, P = 0.004) under the dominant model. The most significant variant associ-
ated with MCS score was located in MAP2K3 (rs1466314) under the dominant model, with patients showing an 
over 2-fold increased risk of a poor MCS score (OR: 2.25, 95% CI: 1.31–3.87, P = 0.003).
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Characteristic N % PCS, Mean (SD) P value
MCS, Mean 
(SD) P value
Age
<50 1,081 16.84 39.05 (11.60) 45.37 (10.89)
50-59 1,672 26.04 39.12 (11.95) 1.000 44.57 (11.33) 0.351
60-69 2,149 33.47 38.50 (11.93) 0.759 46.23 (11.35) 0.221
70+ 1,518 23.64 38.44 (11.59) 0.715 47.48 (11.45) <0.001
P for trend 0.077 <0.001
Sex
Male 3,431 53.46 38.96 (11.90) 46.75 (11.33)
Female 2,987 46.54 38.49 (11.69) 0.109 45.03 (11.29) <0.001
Marital status
Married 4,679 72.93 39.24 (11.75) 46.33 (11.19)
Widowed 635 9.90 37.00 (11.73) <0.001 45.83 (11.84) 0.972
Separated 34 0.53 36.06 (11.91) 0.710 42.19 (11.27) 0.290
Divorced 637 9.93 37.24 (11.64) 0.001 44.13 (11.66) <0.001
Never Married 431 6.72 38.23 (12.30) 0.606 44.96 (11.37) 0.154
Education
<High School 760 12.37 35.17 (11.22) 42.63 (11.81)
High School/Vocational/AA 3,543 57.66 38.02 (11.60) <0.001 45.85 (11.45) <0.001
College Degree 1,842 29.98 41.77 (11.71) <0.001 47.64 (10.59) <0.001
P for trend <0.001 <0.001
Race
Non-Hispanic White 5,268 83.09 38.92 (11.75) 45.97 (11.34)
Hispanic 280 4.42 39.05 (11.73) 1.000 44.56 (11.71) 0.355
Non-Hispanic Black 460 7.26 35.73 (11.97) <0.001 45.21 (11.40) 0.849
Asian/Pacific Islander 217 3.42 40.62 (11.54) 0.316 48.26 (10.68) 0.034
Other 115 1.81 37.80 (12.21) 0.976 47.27 (10.90) 0.918
Alcohol
Never 2,626 41.19 37.19 (11.50) 45.48 (11.58)
Former 1,205 18.90 35.37 (11.21) <0.001 44.48 (11.58) 0.033
Current 2,544 39.91 41.93 (11.64) <0.001 47.14 (10.86) <0.001
P for trend <0.001 <0.001
Smoking
Never 1,112 17.40 40.78 (11.86) 48.02 (10.51)
Former 4,083 63.88 38.85 (11.73) <0.001 46.06 (11.29) <0.001
Current 1,197 18.73 36.47 (11.65) <0.001 43.61 (11.88) <0.001
P for trend <0.001 <0.001
Past Medical History
Yes 5,394 84.43 38.37 (11.78) 45.81 (11.45)
No 995 15.57 40.61 (11.80) <0.001 46.73 (10.66) 0.018
Past Cancer Treatment
Yes 1,845 28.74 35.86 (10.62) 45.39 (11.15)
No 4,575 71.26 39.90 (12.06) <0.001 46.17 (11.41) 0.012
Histology
Non-Small Cell Carcinoma
Adenocarcinoma 2,996 49.32 39.66 (11.82) 46.63 (11.08)
Squamous Cell 973 16.02 38.03 (11.46) 0.003 45.69 (11.73) 0.305
Large Cell 208 3.42 37.36 (11.33) 0.091 45.00 (11.30) 0.500
Non-small cell carcinoma, 
non-specified 972 16.00 37.40 (11.85) <0.001 45.20 (11.38) 0.009
Small Cell 667 10.98 36.84 (11.67) <0.001 43.77 (11.62) <0.001
Other 258 4.25 41.51 (11.92) 0.200 47.65 (11.37) 0.930
Stage
I 621 9.67 43.90 (11.46) 49.28 (10.39)
II 228 3.55 43.68 (11.74) 1.000 50.09 (10.37) 0.988
III 979 15.25 41.16 (11.79) <0.001 46.26 (11.21) <0.001
IV 1,768 27.54 37.74 (11.82) <0.001 45.22 (11.52) <0.001
Unknown 2,824 43.99 37.00 (11.30) <0.001 45.23 (11.34) <0.001
P for trend <0.001 <0.001
Table 1. Host Characteristics and the Association of Demographic, Lifestyle, and Clinical Characteristics with 
PCS and MCS Score.
www.nature.com/scientificreports/
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When analyzing the gene-based analysis results from the VEGAS software, many genes were significant con-
tributors to PCS and MCS scores in the discovery phase (data not shown). For PCS score this included MAPK11 
(P = 0.011) and PEX7 (P = 0.005). For MCS score, this included MAP2K3 (P = 0.002) and TRAF2 (P = 0.023).
In the discovery phase, individuals with homozygous variant genotype of MEF2B: rs2040562 showed a 
3.06-fold increased risk of a poor mental health score (95% CI: 1.05–8.92, P = 0.041), compared to subjects car-
rying at least one major allele. Individuals with homozygous variant genotype of MEF2B: rs2040562 showed a 
2.61-fold increased risk of a poor MCS score (95% CI: 1.11–6.15, P = 0.028) in the validation phase. When we 
combined discovery and validation phase: OR = 2.43, 95% CI: 1.29–4.58, P = 0.006 for rare homozygote genotype 
(Table 2). When analyzing the gene-based analysis results, MAP2K6 was a contributor to PCS score based on the 
discovery phase p-values (P = 0.022) and the validation phase p-values (P = 0.001) (data not shown).
Relationship between PCS/MCS Scores, SNPs, and Survival. Survival analysis in Fig. 2 and Supplemental Table 5 
showed that individuals with a PCS or MCS score less than 50, had an increased risk of death (PCS: HR = 1.63, 
95% CI: 1.51–1.77, P < 0.001, MCS: HR = 1.23, 95% CI: 1.16–1.32, P < 0.001). This increased risk resulted in a 
difference between median survival time (MST) of those with a PCS score less than 50 (MST = 15.1 months) 
and those with a PCS score greater than 50 (MST = 32.1 months, Plog-rank < 0.001) (Figure 2A). There was also a 
reduction in MST for patients with a MCS score less than 50 at only 15.4 months and those with a MCS greater 
than 50 at 21.7 months (Plog-rank < 0.001) (Fig. 2B). When stratifying by stage, this effect was seen in stage III and 
stage IV patients (Figure 2C and D).
Figure 1. Association between Demographic/Clinical Factors and Quality of Life Measures in Lung Cancer 
Patients; (A) PCS scores, (B) MCS scores. Odds ratios adjusted by age, sex, race, marital status, education, 
smoking status, alcohol use, past medical treatment, past treatment, histology, and stage.
Gene: SNP Model MCS <50 WW/WV/VV MCS ≥50 WW/WV/VV OR (95% CI)* P Value
Discovery Phase
MEF2B: rs2040562 Recessive 86/60/23 75/70/7 3.06 (1.05–8.92) 0.041
Validation Phase
Gene: SNP Model MCS <50 WW/WV/VV MCS ≥50 WW/WV/VV OR (95% CI)* P Value
MEF2B: rs2040562 Recessive 62/76/28 56/84/14 2.61 (1.11–6.15) 0.028
Combined Analysis
Gene: SNP Model MCS <50 WW/WV/VV MCS ≥50 WW/WV/VV OR (95% CI) P Value
MEF2B: rs2040562 Recessive 148/136/51 131/154/21 2.43 (1.29–4.58) 0.006
Table 2. Association Between p38 MAPK Validated Variant and MCS Score. *Adjusted for age, sex, marital 
status, education, smoking status, alcohol use, past medical history, past treatment, histology, and stage.
www.nature.com/scientificreports/
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We found that eighteen SNPs were significantly associated with lung cancer five-year survival in the discov-
ery phase (Supplemental Table 6). Patients with this MAP3K5: rs3765259 variant had a decreased risk of dying 
(HR = 0.56, 95% CI: 0.40–0.79, P = 0.0008). Those with the common genotype had a MST of 17.3 months, those 
with one variant allele had a MST of 23.8 months (Plog-rank = 0.053).
Discussion
The importance of a good QOL in cancer patients is well known. To date there have been no studies reported on 
the association of detailed demographic, clinical characteristics, and p38 MAPK genetic variants and QOL in lung 
cancer patients. This study characterizes the epidemiological, clinical, and genetic determinants of QOL in a large 
population of lung cancer patients. Alcohol use, smoking, education, and higher lung cancer stage were consist-
ently shown to impact mean PCS and MCS. Poor PCS and MCS QOL scores were associated with and increased 
risk of death and poor survival. A validated SNP (MEF2B: rs2040562) in the p38 MAPK pathway was associated 
with an increased risk of poor MCS score.
Previous research has found that the majority of smokers who are current smokers when diagnosed with lung 
cancer will continue to smoke regardless of their cancer diagnosis16. In our study, former and current smokers 
reported worse PCS and MCS scores compared to never smokers, and poor QOL in current smokers is consist-
ent with the literature9,10. Former smokers reported slightly higher PCS and MCS scores than current smokers. 
Suggesting that participants who are former smokers do not feel that their QOL is as high as never smokers. This 
presents the possibility of future smoking cessation programs in lung cancer survivors to assist current smokers 
in becoming former smokers with the goal of increasing their QOL and thus, potentially improving long-term 
prognosis.
A previous study examining health perceptions in lung cancer survivors found that current drinkers at diag-
nosis will continue to be current drinkers17. Those that were currently drinking were at a higher risk of reporting 
worse perception of health status17. Interestingly, we found the opposite finding in our analysis for physical QOL 
in newly diagnosed patients. Our analysis is the first to our knowledge that has examined alcohol use and QOL in 
newly diagnosed lung cancer cases. Further analysis is warranted to dissect the potentially complicated relation-
ship between alcohol use and QOL.
There is limited research on the association between education level and QOL in lung cancer patients. A few 
studies found that lower education level is associated with poorer performance status in clinical trial partici-
pants18,19 and higher education is associated with better QOL and lower symptom levels20. Mixed results have 
been seen between education level and different aspects of QOL in NSCLC patients21 and survivors22. Our study 
is the first to examine education level and QOL in a large population of newly diagnosed patients and we found 
patients with a high school degree or higher were more likely to report higher PCS and MCS scores. Further 
research is needed to determine possible disparities underlying the gap between QOL and education level in 
patients.
The p38 MAPK pathway has been associated with QOL and QOL factors such as depression, pain, and there is 
evidence of an association with anxiety in animal models23–25. Individuals diagnosed with major depression have 
increased levels of pro-inflammatory cytokines and corresponding receptors in peripheral blood and cerebral 
Figure 2. 5-year Survival by Quality of Life Measures in Lung Cancer Patients and Cancer Stage; (A) PCS 
scores (B) MCS scores; Scores were dichotomized at 50, representing the mean PCS/MCS score in the general 
population. Scores were dichotomized at 50 and stratified by cancer stage. Hazard Ratios adjusted by age, sex, 
race, smoking status, previous cancer treatment, treatment at MD Anderson, histology, and stage.
www.nature.com/scientificreports/
6SCiEnTifiC RePORTS |  (2018) 8:10640  | DOI:10.1038/s41598-018-25712-1
spinal fluid25,26, and pro-inflammatory cytokines activate the p38 MAPK pathway, which subsequently can acti-
vate the serotonin transporter (SERT)27. Furthermore, research has linked the activation of the p38 MAPK path-
way to regulation of mood-related neurotransmitters, with potential links to the regulation of synaptic plasticity28. 
Our study discovered multiple variants in p38 MAPK pathway genes that were associated with PCS and MCS 
scores. One variant (MEF2B: rs2040562) was replicated in association with mental QOL. Myocyte-enhancing 
factor 2B (MEF2B) protein is a transcription factor that is important in development and adulthood and is impor-
tant in regulating transcriptional programming29. Research has shown that patients with metastatic renal cell 
carcinoma who are depressed (compared to non-depressed patients) show increased expression of MEF230. Our 
results suggest that individuals with a variant in MEF2B are at an increased risk of reporting a poor MCS score 
and further research should be completed to understand the mechanism.
Finally, we identified that individuals with poor reported PCS or MCS scores are at a higher risk of five-year 
mortality and our results support and extend previous findings31–35 that examined QOL during or following 
treatment. We examined QOL at time of diagnosis and studies that examined baseline QOL and survival in lung 
cancer patients support our findings2,3,36–42. These results further highlight that many factors influence survival 
and stress the importance of potential behavioral interventions in the clinical setting to improve QOL and poten-
tially improve survival.
The strengths of this study include a large study population and the ability to assess the relationship of vari-
ous demographic, epidemiological, clinical, and genetic factors with QOL. The main limitation of this study is 
that over 2,800 patients were missing stage information. The results of a sensitivity analysis showed consistency 
between the full model and the reduced model.
In conclusion, we have identified several determinants that contribute to QOL in lung cancer patients. The 
results of this study are important in that they provide an overarching picture of key QOL factors that affect lung 
cancer patients. This information could be used to identify potential interventions to improve QOL, as well as 
those at increased risk of a poor treatment response and prognosis due to their reduced QOL. This could result in 
more of a proactive approach in the clinic to address health behaviors that impact QOL.
Materials and Methods
Study Population and Data Collection. The population was 6420 newly diagnosed lung cancer patients 
from The University of Texas MD Anderson Cancer Center collected from 2000 to 2010. Participants completed 
an institutional patient health intake questionnaire at their initial visit to MD Anderson within one year of diag-
nosis. Since 1999, the SF-12v1 has been part of MD Anderson’s institutional patient intake questionnaire com-
pleted by all new patients at MD Anderson Cancer Center, which also includes demographic and epidemiological 
data. It encompasses four domains of QOL (physical, social, functional, and emotional) and eight subscales (phys-
ical functioning, general health, bodily pain, role physical, vitality, social functioning, role emotional, and mental 
health) formed from the SF-12v1 responses43. These subscales are used to calculate the Physical Component 
Summary (PCS) and Mental Component Summary (MCS) scores. Both the MSC and PCS were normalized to a 
mean of 50 (SD = 10) based on responses to the SF-12v1 among the US general population. A score greater than 
50 indicates a QOL that is better than the general population. The question in the SF-12v1 that asks “During the 
past 4 weeks, how much did pain interfere with your normal work” was modified in the questionnaire as “During 
the past week, has pain interfered with your general activities” and the scoring was adjusted to match the SF-12v1 
scoring. Current alcohol drinkers were participants that self-report drinking at least one alcoholic drink per 
month. Never smokers were participants who had smoked less than 100 cigarettes in their lifetime. Clinical data 
were obtained from MD Anderson’s Tumor Registry. Individuals with multiple primary tumors were excluded, 
except for multiple lung tumors. The participants provided written informed consent and the study was approved 
by the Institutional Review Board at The University of Texas MD Anderson Cancer Center. All methods were 
performed in accordance with the relevant guidelines and regulations.
DNA Isolation and Genotyping. A subset of patients (N = 641) have data on 218 SNPS in 20 genes from 
the p38 MAPK pathway. DNA isolation and genotyping methods have been previously described44,45. In short, 
inflammation pathway-related genes were identified through the Gene Oncology database46,47 and the National 
Center for Biotechnology Information (NCBI) Pubmed48. Haplotype tagging SNPs were selected for each gene 
10 kb upstream of the transcriptional start site or 10 kb downstream of the transcriptional stop site. SNPs in the 
coding (nonsynonymous SNPs and synonymous SNPs) and regulatory regions (splicing site, promoter, 5′UTR, 
and 3′UTR). In addition, SNPs previously reported to be associated with cancer and functional SNPs were 
included. Genotyping was completed using the Illumina Infinium iSelect HD Custom Genotyping BeadChip.
Statistical Analysis. To analyze the difference in mean PCS and MCS scores between categories of host 
characteristics, t-test or ANOVA with pairwise comparison testing was used (SIDAK test). Non-parametric tests 
were completed as well and the results were similar. The parametric results are reported. PCS and MCS were 
dichotomized by 50 to assess the association of demographic and clinical variables with QOL. Unconditional 
multivariable logistic regression was used to calculate odd ratios (ORs) and 95% confidence intervals (CIs). 
Confounders were adjusted for in the PCS and MCS multivariable models (age, sex, marital status, education, 
smoking status, alcohol use, past medical history, past treatment, histology, and stage). A sensitivity analysis was 
completed and found no major differences between the full data (missing stage categorized as unknown) and the 
reduced data (missing stage removed) (Supplemental Figs 3 and 4). The full dataset was used. For the effect of 218 
SNPs in the p38 MAPK pathway on PCS and MCS risk, unconditional multivariable logistic regression was used 
to estimate ORs and 95% Cis (age, sex, marital status, education, smoking status, alcohol use, past medical his-
tory, past treatment, histology, and stage). Dominant, recessive, and additive models of inheritance were assessed 
for each SNP. The study sample was divided into two groups by assigning alternating samples into the discovery 
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set and the validation set. Q-Values were also calculated to test for multiple comparisons in the discovery phase 
(data not shown). We tested all of the variants from the discovery phase that had a p-value of less than 0.05 in the 
validation phase of the genetic analysis. Multivariable Cox regression was used to estimate hazard ratios (HR) 
and 95% CI for all survival analyses (adjusted for age, sex, race, smoking status, previous cancer treatment, treat-
ment at MD Anderson, histology, and cancer stage). The effects of PCS and MCS scores on five-year lung cancer 
survival (calculated using the diagnosis date and last contact date) were estimated. Kaplan-Meier survival curves 
and log-rank tests were calculated to analyze the difference in five-year survival times. Statistics were completed 
using STATA 13 (Stata Corporation, College Station, TX). Statistical tests were two sided and a p-value of less 
than 0.05 was considered significant. VEGAS software was used to perform a gene-based interaction analysis49. In 
the VEGAS analysis, significant variants were carried forward and the validation set was analyzed using the same 
model that was most significant in the discovery phase.
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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